AstraZeneca (AZN) Stock Rating Reaffirmed by Jefferies Group

AstraZeneca (LON:AZN)‘s stock had its “buy” rating restated by research analysts at Jefferies Group in a research report issued on Monday, May 14th, MarketBeat reports.

A number of other equities research analysts have also recently commented on the stock. Barclays set a GBX 6,500 ($87.21) target price on shares of AstraZeneca and gave the company a “buy” rating in a research report on Friday, May 11th. Shore Capital reiterated a “hold” rating on shares of AstraZeneca in a research report on Friday, May 11th. Credit Suisse Group restated an “outperform” rating on shares of AstraZeneca in a research report on Friday, May 4th. JPMorgan Chase restated an “overweight” rating on shares of AstraZeneca in a research report on Wednesday, April 25th. Finally, Goldman Sachs set a GBX 3,750 ($50.32) price objective on shares of AstraZeneca and gave the stock a “sell” rating in a research report on Tuesday, April 24th. Four research analysts have rated the stock with a sell rating, six have assigned a hold rating and fourteen have assigned a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus price target of GBX 5,253.43 ($70.49).

Shares of AstraZeneca traded up GBX 37 ($0.50), reaching GBX 5,454 ($73.18), during mid-day trading on Monday, according to MarketBeat. The company’s stock had a trading volume of 2,149,253 shares, compared to its average volume of 2,310,000. AstraZeneca has a 1-year low of GBX 4,260 ($57.16) and a 1-year high of GBX 5,520 ($74.06).

About AstraZeneca

AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.

Analyst Recommendations for AstraZeneca (LON:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.



Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit